BridgeBio (BBIO) CAO awarded 14,170 RSUs in new equity grant

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. reported that Chief Accounting Officer Maricel Apuli received a grant of 14,170 restricted stock units (RSUs) of common stock as equity compensation. The award was made at no cash cost to Apuli and increases her direct holdings to 136,115 shares.

The RSUs vest over time, with 1/16 of the units scheduled to vest on May 16, 2026, and 1/16 vesting each quarter thereafter until fully vested, contingent on her continued service with BridgeBio or its subsidiaries. Each RSU converts into one share of common stock upon vesting, providing long-term, service-based incentive alignment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Apuli Maricel

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,170	$0.00	--

Holdings After Transaction: Common Stock — 136,115 shares (Direct)

Footnotes (1)

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2026, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A(1)		14,170	A	$0(2)	136,115	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2026, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Remarks:

	/s/ Maricel Apuli	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BridgeBio Pharma (BBIO) report for Maricel Apuli?

BridgeBio reported that Chief Accounting Officer Maricel Apuli received 14,170 restricted stock units of common stock as an equity grant. The award was recorded at zero cash cost and represents a compensation-related acquisition, not an open-market purchase or sale.

How many BridgeBio (BBIO) shares does Maricel Apuli hold after this Form 4?

After the RSU grant, Maricel Apuli is reported to beneficially own 136,115 shares of BridgeBio common stock. This figure includes the newly awarded restricted stock units that will settle into shares as they vest over the stated multi-year schedule.

How do the new BridgeBio (BBIO) RSUs granted to Maricel Apuli vest?

The RSUs vest over four years, with 1/16 of the underlying shares vesting on May 16, 2026, and 1/16 vesting each quarter thereafter. Vesting is conditioned on Apuli’s continued service with BridgeBio or its subsidiaries on each scheduled vesting date.

What does each RSU granted to Maricel Apuli by BridgeBio (BBIO) represent?

Each restricted stock unit represents a contingent right to receive one share of BridgeBio’s common stock. Shares are delivered only as the RSUs vest over time, making this a form of deferred equity compensation tied to ongoing employment.

Was Maricel Apuli’s BridgeBio (BBIO) RSU grant an open-market stock purchase?

No. The filing describes the transaction as a grant or award acquisition at a price of $0.00 per share. This indicates a compensation-related equity award, not an open-market purchase of BridgeBio shares on a stock exchange.

Under which plan were the BridgeBio (BBIO) RSUs for Maricel Apuli granted?

The restricted stock units were granted under BridgeBio’s 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. This plan provides equity-based awards intended to align employee incentives with long-term shareholder interests.